Quadriga Capital Funds have reached an agreement to sell Kinetics to Exyte. Pending regulatory approvals, this strategic move marks a significant advancement for Kinetics at the end of Quadriga Capital’s holding period. With a dedicated internationalisation strategy, Kinetics experienced remarkable organic growth and expanded its offerings through strategic acquisitions. During the investment period, Kinetics saw a fivefold increase in revenues and quadrupled its employee base. Teaming up with Exyte will further enhance Kinetics' ability to cater to the semiconductor and biopharma industries' needs.